Mirador Capital Partners LP Acquires 1,010 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Mirador Capital Partners LP raised its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 1.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 65,636 shares of the biopharmaceutical company’s stock after acquiring an additional 1,010 shares during the quarter. Mirador Capital Partners LP’s holdings in Cytokinetics were worth $3,088,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Louisiana State Employees Retirement System boosted its position in shares of Cytokinetics by 0.6% during the 3rd quarter. Louisiana State Employees Retirement System now owns 32,600 shares of the biopharmaceutical company’s stock worth $1,721,000 after purchasing an additional 200 shares in the last quarter. UMB Bank n.a. boosted its position in shares of Cytokinetics by 65.6% during the 3rd quarter. UMB Bank n.a. now owns 601 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 238 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in Cytokinetics by 2.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 15,062 shares of the biopharmaceutical company’s stock valued at $795,000 after acquiring an additional 430 shares in the last quarter. MetLife Investment Management LLC lifted its position in Cytokinetics by 0.4% in the 3rd quarter. MetLife Investment Management LLC now owns 123,308 shares of the biopharmaceutical company’s stock valued at $6,511,000 after acquiring an additional 538 shares in the last quarter. Finally, Blue Trust Inc. lifted its position in Cytokinetics by 225.9% in the 3rd quarter. Blue Trust Inc. now owns 981 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 680 shares in the last quarter.

Insider Activity at Cytokinetics

In other Cytokinetics news, Director Wendall Wierenga sold 4,452 shares of the firm’s stock in a transaction on Monday, October 28th. The shares were sold at an average price of $52.25, for a total value of $232,617.00. Following the completion of the transaction, the director now directly owns 24,559 shares of the company’s stock, valued at $1,283,207.75. This trade represents a 15.35 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Fady Ibraham Malik sold 7,300 shares of the firm’s stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $51.91, for a total transaction of $378,943.00. Following the completion of the transaction, the executive vice president now directly owns 114,920 shares of the company’s stock, valued at approximately $5,965,497.20. The trade was a 5.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 52,216 shares of company stock worth $2,707,436. Corporate insiders own 3.40% of the company’s stock.

Cytokinetics Trading Down 1.4 %

Shares of CYTK stock opened at $46.20 on Thursday. The company has a 50 day moving average of $50.01 and a 200-day moving average of $53.33. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 5.93. Cytokinetics, Incorporated has a 12-month low of $44.49 and a 12-month high of $86.63. The firm has a market cap of $5.45 billion, a P/E ratio of -8.59 and a beta of 0.82.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.09). The firm had revenue of $0.46 million for the quarter, compared to the consensus estimate of $1.21 million. During the same period in the prior year, the firm posted ($1.35) EPS. The firm’s revenue was up 22.5% compared to the same quarter last year. Sell-side analysts anticipate that Cytokinetics, Incorporated will post -5.23 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on CYTK. Mizuho raised their price target on shares of Cytokinetics from $99.00 to $103.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. HC Wainwright reaffirmed a “buy” rating and issued a $120.00 price target on shares of Cytokinetics in a research report on Friday, January 10th. Royal Bank of Canada lifted their target price on shares of Cytokinetics from $80.00 to $82.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 18th. JMP Securities reissued a “market outperform” rating and set a $78.00 target price on shares of Cytokinetics in a research report on Tuesday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Cytokinetics in a research report on Friday, October 18th. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $83.64.

Cytokinetics Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.